The global genome editing market is rapidly increasing due to the increased government funding for genomics technology, rise in the production of genetically modified crops and technological advancements these all factors are driving the growth of this market.
Recent developments across genome editing technologies have resulted in the creation of next generation nucleases that have higher levels of accuracy when correcting genetic mutations and defects. The classes under the genome editing technologies are the 4 broad families of nucleases: ZFNs, TALENs, CRISPR/Cas9, and Meganucleases.
Gene editing technologies have an impact across multiple applications areas including plant and animal genetic engineering. However, the area of most disruption is across human cell line engineering, which enables the development of next generation’s therapies and drugs. However, the agricultural industry has seen more success with gene editing techniques largely due to the less stringent regulatory environment.
This market research report categorizes the genome editing market into the following segments:
• Antisense Technology
• Other Technologies
• Cell Line Engineering
• Animal Genetic Engineering
• Plant Genetic Engineering
• Other Applications
By End User
• Biotechnology and Pharmaceutical Companies
• Government and Academic Research Institutes
• Other Research Organizations
By Geographical Region
• North America
• Rest of the World
1.1 KEY TAKE AWAYS
1.2 REPORT DESCRIPTION
1.3 MARKETS COVERED
1.5 RESEARCH METHODOLOGY
1.5.1 MARKET SIZE
1.5.2 MARKET SHARE
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES
2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
184.108.40.206 Key Data From Primary Sources
220.127.116.11 Key Industry Insights
2.3 Market Size Estimation Methodology
2.3.1 Market Data Validation and Triangulation
2.3.2 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Genome Editing: Market Overview
4.2 Geographic Analysis: Genome Editing Market, By Application (2016)
4.3 Market Size, By Technology, 2016 vs 2021
4.4 Market Size, By Application, 2016 vs 2021
4.5 Market Size, By End User, 2016 vs 2021
4.6 Geographical Snapshot of the Genome Editing Market
5 Market Overview
5.2 Market Dynamics
18.104.22.168 Rising Government Funding and Growth in the Number of Genomics Projects
22.214.171.124 High Prevalence Rate of Infectious Diseases and Cancer Among Patients
126.96.36.199 Technological Advancements
188.8.131.52 Increase in Demand for Synthetic Genes
184.108.40.206 Rise in Production of Genetically Modified Crops
220.127.116.11 Increasing Awareness About Genomics
18.104.22.168 New Product Launches By Industry Players
22.214.171.124 High Cost of Genomic Equipment
126.96.36.199 Adverse Public Perception Related to Genetic Research
188.8.131.52 Use of Genome Editing in Specialized/Personalized Medicine
184.108.40.206 Emerging Markets in Developing Countries
220.127.116.11 Off-Target Effect of CRISPR
18.104.22.168 Shortage of Trained Professionals
6 Global Genome Editing/Engineering Market, By Technology
6.6 Other Technologies
7 Global Genome Editing/Genome Engineering Market, By Application
7.2 Cell Line Engineering
7.3 Animal Genetic Engineering
7.4 Plant Genetic Engineering
7.5 Other Applications
8 Global Genome Editing/Engineering Market, By End User
8.2 Biotechnology & Pharmaceutical Companies
8.3 Academic & Government Research Institutes
8.4 Contract Research Organizations
9 Genome Editing/Genome Engineering Market, By Region
9.2 North America
22.214.171.124 Development of Gene Therapy in the U.S.
126.96.36.199 Increasing Use of Gm Crops
188.8.131.52 Prevalence of Alzheimer’s Disease and Other Dementias in the United States
184.108.40.206 Genome Editing Conferences in the U.S.
220.127.116.11 Rising Availability of Research Grants and Funding
18.104.22.168 Genome Editing Standards Workshop in the U.S.
22.214.171.124 Increasing Prevalence of Cancer
126.96.36.199 Strategic Developments in the U.S. Market
188.8.131.52 Availability of Research Funding in Canada
184.108.40.206 Rising Incidence of Cancer
220.127.116.11 Gapp to Intensify Genomic R&D
9.3.1 Conferences and Meetings in Europe
18.104.22.168 Increased Funds, and Grants By Government Bodies
22.214.171.124 100,000 Genomes Project in U.K.
126.96.36.199 Availability of Funding for Life Science Research
188.8.131.52 Conferences/Meetings/ Symposiums/Workshops in Germany
184.108.40.206 Spain’s Focus on Research
220.127.116.11 Growth in the Italian Biotech and Pharma Sectors
18.104.22.168 Growing Research Investments in Sweden & Denmark
22.214.171.124 High Intensity of R&D Activities in China
126.96.36.199 Growing Focus of Global Companies on China
188.8.131.52 Involvement of Industry Players in the Japanese Market: Significant Developments
184.108.40.206 Conferences and Symposiums on Genetic Engineering in Japan
220.127.116.11 Focus on Cancer Research and Treatment
18.104.22.168 Emergence of Local Players in India
22.214.171.124 Growth of the Pharmaceutical Industry in India
126.96.36.199 Development of Bio-Clusters to Boost India’s Biotechnology Industry
188.8.131.52 Australia: Availability of Financial Support for Research
184.108.40.206 Genome Asia 100k Initiative
220.127.116.11 Crop Research Initiatives in Asia
9.5.1 Genetic Testing and Genomic Analysis in the Middle East
9.5.2 Brazil: Investments in Research and Innovation Centers and Conferences & Workshops
9.5.3 Rising Prevalence of Hiv, Cancer in Africa
10 Competitive Landscape
10.2 Market Share Analysis
10.2.2 Thermo Fisher Scientific, Inc.
10.2.3 Merck KGaA
10.2.4 Horizon Discovery Group PLC
10.3 Competitive Situation and Trends
10.3.1 Agreements, Collaborations, and Partnerships
10.3.2 Product & Service Launches
10.3.5 Other Strategies
10.4 Strategic Benchmarking
11 Company Profiles
11.1 Thermo Fisher Scientific, Inc.
11.2 Merck KGaA
11.3 Horizon Discovery Group PLC
11.4 Genscript USA Inc.
11.5 Sangamo Biosciences, Inc.
11.6 Integrated DNA Technologies, Inc.
11.7 Lonza Group Ltd.
11.8 New England Biolabs, Inc.
11.9 Origene Technologies, Inc.
11.10 Transposagen Biopharmaceuticals, Inc.
|Single User License||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|
|Multi User License||The report will be emailed to you. The report is sent in PDF format.||This is a 1-5 user license, allowing up to five users to have access to the product.|
|Corporate License||The report will be emailed to you. The report is sent in PDF format.||This is a 10+ user license, allowing up to 10+ users to have access to the product.|
|Mini Report License||In this you will receive full report except the Company Profile section of this report.||In this you will receive full report except the Company Profile section of this report.|
Toll Free No. : +1-855-984-1862
Call Us. : +91 86 05 657204